Market Research Logo

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015’, provides an overview of the Hospital Acquired Pneumonia (HAP)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hospital Acquired Pneumonia (HAP) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) Overview
Therapeutics Development
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes
Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hospital Acquired Pneumonia (HAP) - Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
Achaogen Inc.
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Cardeas Pharma Corp.
Dong-A Socio Group
MedImmune, LLC
Meiji Seika Pharma Co., Ltd.
Melinta Therapeutics, Inc
Merck & Co., Inc.
Motif Bio Plc
Nabriva Therapeutics AG
Savara Inc.
Serendex Pharmaceuticals A/S
Tetraphase Pharmaceuticals Inc.
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(amikacin + fosfomycin) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ceftazidime + avibactam sodium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AA-139 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
arbekacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eravacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iclaprim mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lefamulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-3902 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-4893 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panaecin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pseudomonas + VAP vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pseudomonas aeruginosa vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Qn-2251 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
relebactam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tosatoxumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vancomycin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hospital Acquired Pneumonia (HAP) - Recent Pipeline Updates
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA
Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline’s Potential Activity in Treating Serious Respiratory Infections
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation
Jan 07, 2013: Trius Therapeutics's Tedizolid Receives Qualified Infectious Disease Product Designation From FDA
Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2015
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Group, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc., H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Serendex Pharmaceuticals A/S, H2 2015
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hospital Acquired Pneumonia (HAP) Therapeutics - Recent Pipeline Updates, H2 2015
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2015
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2015
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report